| Primary |
| Chronic Myeloid Leukaemia |
49.3% |
| Gastrointestinal Stromal Tumour |
20.2% |
| Acute Lymphocytic Leukaemia |
14.8% |
| Leukaemia |
1.8% |
| Prophylaxis |
1.6% |
| Diabetes Mellitus |
1.2% |
| Hypereosinophilic Syndrome |
1.2% |
| Metastatic Neoplasm |
1.0% |
| Prophylaxis Against Graft Versus Host Disease |
1.0% |
| Suicide Attempt |
1.0% |
| Acute Myeloid Leukaemia |
0.8% |
| Deep Vein Thrombosis |
0.8% |
| Dermatofibrosarcoma |
0.8% |
| Graft Versus Host Disease |
0.8% |
| Antibiotic Therapy |
0.6% |
| Blast Crisis In Myelogenous Leukaemia |
0.6% |
| Corneal Transplant |
0.6% |
| Dyspnoea |
0.6% |
| Hypertension |
0.6% |
| Immunosuppression |
0.6% |
|
| Death |
17.7% |
| Second Primary Malignancy |
7.0% |
| Thrombocytopenia |
6.5% |
| Treatment Failure |
6.5% |
| Premature Baby |
6.0% |
| Vomiting |
6.0% |
| Complications Of Transplant Surgery |
4.7% |
| Pancytopenia |
4.7% |
| Pneumonia |
4.2% |
| Sepsis |
4.2% |
| Therapeutic Response Decreased |
4.2% |
| Weight Increased |
4.2% |
| Pyrexia |
3.7% |
| White Blood Cell Count Decreased |
3.7% |
| Cardiac Failure |
3.3% |
| Drug Resistance |
2.8% |
| Malignant Neoplasm Progression |
2.8% |
| Splenomegaly |
2.8% |
| White Blood Cell Count Increased |
2.8% |
| Maternal Exposure During Pregnancy |
2.3% |
|
| Secondary |
| Acute Lymphocytic Leukaemia |
44.9% |
| Chromosome Analysis Abnormal |
22.5% |
| Chronic Myeloid Leukaemia |
7.5% |
| Prophylaxis |
5.3% |
| Gastrointestinal Stromal Tumour |
3.5% |
| Antifungal Prophylaxis |
3.5% |
| Product Used For Unknown Indication |
2.9% |
| Prophylaxis Against Graft Versus Host Disease |
2.4% |
| Colorectal Cancer |
0.9% |
| Suicide Attempt |
0.9% |
| Hodgkin's Disease |
0.9% |
| Graft Versus Host Disease |
0.8% |
| Pulmonary Arterial Hypertension |
0.7% |
| Acute Undifferentiated Leukaemia |
0.6% |
| Hypereosinophilic Syndrome |
0.6% |
| Leukaemia |
0.5% |
| Non-hodgkin's Lymphoma |
0.5% |
| Bone Marrow Conditioning Regimen |
0.4% |
| Colorectal Cancer Stage Iv |
0.4% |
| Immunosuppression |
0.4% |
|
| Off Label Use |
12.1% |
| Thrombocytopenia |
12.1% |
| Vomiting |
12.1% |
| White Blood Cell Count Decreased |
7.5% |
| Treatment Failure |
6.9% |
| Rash |
5.7% |
| Pancytopenia |
5.2% |
| Suicide Attempt |
5.2% |
| Pancreatitis |
3.4% |
| Respiratory Failure |
3.4% |
| Weight Increased |
3.4% |
| Pneumonia |
2.9% |
| Thrombocytosis |
2.9% |
| Tumour Lysis Syndrome |
2.9% |
| White Blood Cell Count Increased |
2.9% |
| Hepatic Cirrhosis |
2.3% |
| Hepatotoxicity |
2.3% |
| Pancreatic Carcinoma |
2.3% |
| Sepsis |
2.3% |
| Stem Cell Transplant |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
38.6% |
| Drug Use For Unknown Indication |
16.4% |
| Chronic Graft Versus Host Disease |
5.5% |
| Prophylaxis |
5.5% |
| Acute Lymphocytic Leukaemia |
4.7% |
| Hypertension |
4.7% |
| Chronic Myeloid Leukaemia |
3.4% |
| Acute Graft Versus Host Disease |
3.1% |
| Pain |
2.9% |
| Pyoderma Gangrenosum |
2.1% |
| Chemotherapy |
1.8% |
| Infection Prophylaxis |
1.6% |
| Non-small Cell Lung Cancer |
1.6% |
| Cardiac Disorder |
1.3% |
| Her-2 Positive Breast Cancer |
1.3% |
| Stem Cell Transplant |
1.3% |
| Antiviral Prophylaxis |
1.0% |
| B Precursor Type Acute Leukaemia |
1.0% |
| Depression |
1.0% |
| Diabetes Mellitus |
1.0% |
|
| Renal Failure Acute |
12.2% |
| Palpitations |
9.8% |
| Pancytopenia |
7.3% |
| Septic Shock |
7.3% |
| Vomiting |
7.3% |
| Bronchospasm |
4.9% |
| Cytomegalovirus Viraemia |
4.9% |
| Peripheral Sensory Neuropathy |
4.9% |
| Rash Maculo-papular |
4.9% |
| Therapeutic Response Unexpected |
4.9% |
| Thrombocytopenia |
4.9% |
| Type Iii Immune Complex Mediated Reaction |
4.9% |
| Vertigo |
4.9% |
| Agranulocytosis |
2.4% |
| Bronchopulmonary Aspergillosis |
2.4% |
| Cystitis Haemorrhagic |
2.4% |
| Death |
2.4% |
| Disease Progression |
2.4% |
| Disseminated Intravascular Coagulation |
2.4% |
| Drug Level Above Therapeutic |
2.4% |
|
| Interacting |
| Immunosuppression |
17.1% |
| Atrial Fibrillation |
14.3% |
| Chronic Myeloid Leukaemia |
11.4% |
| Eosinophilic Leukaemia |
11.4% |
| Gastrointestinal Stromal Tumour |
11.4% |
| Product Used For Unknown Indication |
11.4% |
| Abdominal Pain |
8.6% |
| Metastases To Peritoneum |
5.7% |
| Primary Hypothyroidism |
5.7% |
| Mineral Supplementation |
2.9% |
|
| Renal Impairment |
31.3% |
| Transplant Rejection |
18.8% |
| Drug Interaction |
12.5% |
| Vomiting |
12.5% |
| Hepatotoxicity |
6.3% |
| Nausea |
6.3% |
| Periorbital Oedema |
6.3% |
| Tumour Lysis Syndrome |
6.3% |
|
